volume 41, issue 4, Pe65-e69 2013
DOI: 10.1016/j.jcms.2012.10.014
View full text
Sarina E.C. Pichardo, Sophie C.C. Kuypers, J.P. Richard van Merkesteyn

Abstract: In the treatment of osteoporosis, M. Kahler and bone metastases from prostate and breast cancer bisphosphonates play a major role. Not all patients respond well to bisphosphonate treatment. Since a few years adverse effects of these drugs have been reported. A new drug, denosumab, a fully human monoclonal antibody to RANKL, has recently been developed. This case reports a 74-year-old male patient with a medical history of diabetes mellitus, angina pectoris, coronary bypasses, hypertension, and prostate cancer …

expand abstract